VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) specialized in Lentiviral vectors. VIVE is focused on the manufacture of Research, Preclinical toxicology and GMP-grade lentiviral vectors. Sealed as Excellence Centre by European Union, VIVEbiotech is currently working with Companies based both in Europe and USA being our main interest adapting to Customer requirements considering also planning and timelines related issues. Importanly, VIVEbiotech is also developing its Lentiviral vector related technology, LENTISOMA. LENTISOMA´s technology is a non-Integrative replicative episomal lentiviral vector .
Location: Spain, Autonomous Community of the Basque Country, San Sebastián
Employees: 51-200
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Stellum Ca... | stellumcap... |
Mentions in press and media 7
| Date | Title | Description |
| 09.12.2024 | The Rise of Earth Imagery and Automated Analytics: A New Era in Technology | In the fast-paced world of technology, two companies are making waves. Spexi and Abselion are harnessing innovation to reshape industries. They recently secured significant funding, propelling their missions forward. Spexi, based in Vancouv... |
| 09.12.2024 | Spexi Raises $11.5M in Series A Funding | Spexi, a Vancouver, Canada-based earth imagery company, raised $11.5M in Series A funding. The round was led by Blockchange Ventures. The company intends to use the funds to expand operations and its development efforts. Led by CEO Bill Lak... |
| 09.12.2024 | VIVEbiotech Receives Investment from Ampersand Capital Partners | VIVEbiotech, a San Sebastian, Spain-based lentiviral vector contract development and manufacturing organization (CDMO), received a growth equity investment from Ampersand Capital Partners. The amount of the deal was not disclosed. As part o... |
| 08.06.2021 | El CDTI destina en mayo más de €2,2M a cinco nuevas coinversiones en capital riesgo a través de Innvierte | 08/06/2021 Nota de prensa EL CDTI DESTINA EN MAYO MÁS DE €2,2 MILLONES A CINCO NUEVAS COINVERSIONES EN CAPITAL RIESGO A TRAVÉS DE INNVIERTE. El CDTI, entidad pública adscrita al Ministerio de Ciencia e Innovación y promotor y accionista ... |
| 04.06.2021 | VIVEbiotech, participada por Inveready y EASO Ventures, inaugura su nueva sede y multiplica por 30 su capacidad de producción de vectores virales | 04/06/2020 Nota de prensa VIVEBIOTECH, PARTICIPADA POR INVEREADY Y EASO VENTURES, INAUGURA SU NUEVA SEDE Y MULTIPLICA POR 30 SU CAPACIDAD DE PRODUCCIÓN DE VECTORES VIRALES. En el acto inaugural ha participado el lehendakari, y han estado ... |
| 09.07.2020 | El CDTI invierte junto a Inveready Biotech III y EASO Ventures en VIVEbiotech | 08/07/2020 Nota de prensa EL CDTI INVIERTE JUNTO A INVEREADY BIOTECH III Y EASO VENTURES EN VIVEBIOTECH. El CDTI, a través de su programa Innvierte, conjuntamente con Inveready Biotech III y EASO Ventures, han alcanzado un acuerdo con lo... |
| 09.09.2019 | Vivebiotech cierra una ronda de €3,5M liderada por Inveready y Easo Ventures. Acuden también la mayoría de socios actuales | 09/09/2019 Nota de prensa VIVEBIOTECH CIERRA UNA RONDA DE €3,5 MILLONES LIDERADA POR INVEREADY Y EASO VENTURES. ACUDEN TAMBIÉN LA MAYORÍA DE SOCIOS ACTUALES. Vivebiotech, con sede en Donosti-San Sebastián ha cerrado una ampliación de cap... |